Cardiometabolic & kidney

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: The DANFLU-2 Trial Subgroup Analysis

J Am Coll CardiolPublished Secondary analysis of the DANFLU-2 randomised trial

Authors' conclusion

In this prespecified analysis of DANFLU-2, including the largest CKD population ever in an individually randomized vaccine trial, we observed a benefit of HD-IIV vs SD-IIV against hospitalization for influenza or pneumonia, as well as hospitalization for influenza, with suggestion of a greater relative benefit among those with CKD.

Study context

Population
Older adults in Denmark, 2022–2023 to 2024–2025 influenza seasons, by presence of chronic kidney disease (CKD)46,788 (14.1%) with CKD
Participants
332,438 adults
Comparison
High-dose inactivated influenza vaccine (HD-IIV) vs standard-dose inactivated influenza vaccine (SD-IIV), by CKD status
Primary endpoint
Hospitalization for influenza or pneumonia (rVE), by CKD status
Methodological detailsprespecified secondary analysis, pragmatic, open-label, individually randomized
  • Prespecified secondary analysis
  • Pragmatic
  • Open-label
  • Individually randomized

Primary result

As reported in the abstract

Hospitalization for influenza or pneumonia
HD-IIV vs SD-IIVAbsolute risk reduction (95% CI)
CKD; NNT = 359
−0.29%(−0.50% to 0.058%)

Relative effectiveness (rVE)

CKD
16.9% (95% CI 3.4%–28.5%)
No CKD
0.6% (95% CI −9.6% to 9.9%)

Further findings

OutcomerVE (95% CI)
Influenza hospitalization, by CKD statusHD-IIV vs SD-IIV · CKD; NNT = 56168.6% (46.7%–82.3%)
Influenza hospitalization, by CKD statusHD-IIV vs SD-IIV · no CKD; NNT =3,95330.6% (7.2%–48.2%)
  • Influenza hospitalization, by CKD status: P interaction = 0.0079

Hospitalization for cardiorespiratory disease, CVD, HF, laboratory-confirmed influenza

Reductions consistent regardless of CKD
all P interaction > 0.05

Original publication

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: The DANFLU-2 Trial Subgroup Analysis. J Am Coll Cardiol. Published 26 November 2025. doi:10.1016/j.jacc.2025.10.005

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.